Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study
Charlotte-Paige Rolle,
Jamie Castano,
Vu Nguyen
et al.
Abstract:Background
In TANGO and SALSA, switching to dolutegravir/lamivudine (DTG/3TC) was noninferior compared to continuing baseline regimen in treatment-experienced adults, however few switched from bictegravir (B)/emtricitabine (F)/tenofovir alafenamide (TAF). Here, we present efficacy and safety of switching to DTG/3TC compared with continuing B/F/TAF in virologically suppressed adults.
Methods
DYAD is an open-label clinical tria… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.